Liver function may change how tirabrutinib acts in the body

NCT ID NCT07198087

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This completed Phase 1 study looked at how the drug tirabrutinib is processed in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Forty participants took a single oral dose, and researchers measured drug levels and safety. The goal was to understand if liver problems affect how the drug behaves, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
tirabrutinib
What this could lead to
If successful, this study could help doctors decide the right dose of tirabrutinib for patients with liver problems, making treatment safer and more effective.
What could go wrong
This is an early-phase study focused on drug processing, not on treating the disease. Results may not directly improve patient outcomes, and liver impairment can affect drug safety unpredictably.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arizona Liver Health

    Chandler, Arizona, 85225, United States

  • Orlando Clinical Research Center, Inc.

    Orlando, Florida, 32809, United States

  • Panax Clinical Research

    Miami Lakes, Florida, 33014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.